abiraterone has been researched along with dutasteride in 8 studies
| Studies (abiraterone) | Trials (abiraterone) | Recent Studies (post-2010) (abiraterone) | Studies (dutasteride) | Trials (dutasteride) | Recent Studies (post-2010) (dutasteride) |
|---|---|---|---|---|---|
| 942 | 97 | 854 | 728 | 188 | 480 |
| Protein | Taxonomy | abiraterone (IC50) | dutasteride (IC50) |
|---|---|---|---|
| 3-oxo-5-alpha-steroid 4-dehydrogenase 1 | Homo sapiens (human) | 0.004 | |
| 3-oxo-5-alpha-steroid 4-dehydrogenase 2 | Homo sapiens (human) | 0.0001 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Balk, SP; Jiang, Z; Kantoff, PW; McKay, RR; Melnick, K; Montgomery, B; Smith, SE; Taplin, ME; Voznesensky, O; Werner, L; Wu, JS; Yuan, X; Zukotynski, KA | 1 |
| Adomat, H; Deb, S; Gleave, M; Guns, ES; Hosseini-Beheshti, E; Ming, DS; Pham, S; Zoubeidi, A | 1 |
| Balk, SP; Bubley, GJ; Cai, C; Chen, EJ; Gao, S; Kantoff, PW; Lis, RL; Loda, M; Montgomery, RB; Nelson, PS; Schaefer, R; Sowalsky, AG; Taplin, ME; Troncoso, P; True, LD; Voznesensky, O; Ye, H | 1 |
| Abazeed, M; Alyamani, M; Auchus, RJ; Balk, SP; Li, J; Li, Z; Rogacki, K; Sharifi, N; Taplin, ME; Upadhyay, SK | 1 |
| Balk, SP; Bhasin, M; Bubley, GJ; Domachevsky, L; Kantoff, PW; Lis, R; Marck, BT; Matsumoto, AM; McKay, RR; Montgomery, B; Mostaghel, EA; Taplin, ME; Voznesensky, O; Werner, L; Zhang, Z; Zukotynski, KA | 1 |
| Deng, T; Ge, R; Lin, X; Long, X; Olumi, AF; Taplin, ME; Wang, H; Wang, Z; Wu, CL; Wu, S; Zhang, Z | 1 |
| Egawa, S; Eto, M; Haginaka, J; Horiyama, S; Inoue, R; Kanji, H; Kobayashi, K; Matsuyama, H; Shiota, M; Tashiro, K | 1 |
4 trial(s) available for abiraterone and dutasteride
| Article | Year |
|---|---|
Imaging, procedural and clinical variables associated with tumor yield on bone biopsy in metastatic castration-resistant prostate cancer.
Topics: Aged; Androgen Antagonists; Androstenes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Azasteroids; Biopsy; Bone Neoplasms; Drug Resistance, Neoplasm; Dutasteride; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Radiography, Interventional; Radionuclide Imaging; Radiopharmaceuticals; Surgery, Computer-Assisted; Technetium Tc 99m Medronate | 2014 |
A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer.
Topics: Aged; Androgens; Androstenes; Disease Progression; Drug Resistance, Neoplasm; Dutasteride; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Radiography; Receptors, Androgen | 2017 |
Methylation of SRD5A2 promoter predicts a better outcome for castration-resistant prostate cancer patients undergoing androgen deprivation therapy.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Androstenes; DNA Methylation; Dutasteride; Epigenesis, Genetic; Humans; Male; Membrane Proteins; Prognosis; Promoter Regions, Genetic; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2020 |
A Phase II Trial of Abiraterone With Dutasteride for Second-Generation Antiandrogen- and Chemotherapy-Naïve Patients With Castration-Resistant Prostate Cancer.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Abiraterone Acetate; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Dutasteride; Humans; Male; Membrane Proteins; Multienzyme Complexes; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2023 |
4 other study(ies) available for abiraterone and dutasteride
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Next-generation steroidogenesis inhibitors, dutasteride and abiraterone, attenuate but still do not eliminate androgen biosynthesis in 22RV1 cells in vitro.
Topics: Androgen Antagonists; Androgens; Androstenes; Androstenols; Azasteroids; Cell Line, Tumor; Dehydroepiandrosterone; Dutasteride; Humans; Kallikreins; Progesterone; Prostate-Specific Antigen; Receptors, Androgen | 2014 |
Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; DNA Helicases; DNA-Binding Proteins; Drug Resistance, Neoplasm; Dutasteride; Humans; Ketoconazole; Leuprolide; Male; Middle Aged; Mutation; Progesterone; Prostatic Neoplasms, Castration-Resistant; PTEN Phosphohydrolase; Receptors, Androgen; Steroid 17-alpha-Hydroxylase | 2015 |
Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Abiraterone Acetate; Administration, Oral; Androgen Antagonists; Androgens; Androstenes; Animals; Cell Line, Tumor; Disease Progression; Dutasteride; Humans; Male; Mice; Oxidation-Reduction; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Xenograft Model Antitumor Assays | 2016 |